Breakthrough Clinical Results
A large-scale Danish register-based study involving over 1 million children found no association between aluminum in childhood vaccines and 50 health conditions, including autism, asthma, and autoimmune diseases. The study, conducted by the Statens Serum Institut (SSI), analyzed data from children born between 1997 and 2018. Researchers used Denmark's national health registers to investigate the link between aluminum-containing vaccines and various health outcomes. The findings reaffirm the safety of Denmark's childhood vaccination program and provide strong evidence against claims linking vaccines to adverse health effects. The study's publication comes amidst ongoing international debates about vaccine safety, highlighting the importance of relying on robust scientific evidence.
Key Highlights
- No association found between aluminum in childhood vaccines and 50 health conditions, including autism.
- Study involved over 1 million Danish children born between 1997 and 2018.
- Findings reaffirm the safety of Denmark's childhood vaccination program.
- Results published in the Annals of Internal Medicine.
Latest Global Estimates of Autism Prevalence and Incidence
According to the Global Burden of Disease Study 2021, autism spectrum disorders (ASD) contributed to 61,823,540 prevalence and 11,544,038 DALYs globally in 2021. A comprehensive systematic review and meta-analysis conducted from 2008 to July 2021 found that the global prevalence of ASD was 0.6% (95% confidence interval: 0.4-1%).
The regional prevalence of ASD varies significantly by continent: - Asia: 0.4% (95% CI: 0.1-1) - America: 1% (95% CI: 0.8-1.1) - Europe: 0.5% (95% CI: 0.2-1) - Africa: 1% (95% CI: 0.3-3.1) - Australia: 1.7% (95% CI: 0.5-6.1)
More specific regional studies provide additional insights: - In New South Wales, Australia (2002-2015), the prevalence of ASD in a population-based cohort was 1.3% by age 12, with prevalence at age 6 increasing an average of 4.1% per year - A Bahrain study found an ASD prevalence of 5.10 per 1,000 children based on screening with the Modified Checklist for Autism in Toddlers-Revised (MCHAT-R) - In Egypt, a 2025 study found ASD prevalence was 1.1% among children aged 12 months to 12 years, with significant geographic variability between urban and rural areas - A hospital-based study in Cameroon (2021-2022) reported a hospital ASD prevalence of 3.7% among children aged 2-15 years
Demographic patterns consistently show higher prevalence in certain populations: - Males and younger adults were identified as high-risk populations for ASD - In Egypt, boys were four times more affected than girls, with prevalence rates of 1.7% and 0.4%, respectively - In Cameroon, children with ASD were mainly males (76%) and aged 4-5 years (37.93%)
The temporal trends indicate that from 1990 to 2021, the number of cases increased, and predictions show that the disease burden for both genders would continue to increase from 2022 to 2046. According to one report, 1 out of every 58 newly-born children is suffering from autism.
Socioeconomic factors also play a role in ASD prevalence: - Higher socio-demographic index (SDI) regions were found to be high-risk areas for autism - A 2010 US study found that ASD prevalence increased with increasing socioeconomic status (SES) in a dose-response manner - A Danish study (2015) found that changes in reporting practices could account for most (60%) of the increase in observed ASD prevalence
The burden of ASD among females may be underestimated, and the aging process has highlighted the urgent need to address ASD in the elderly population. ASD imposes a heavy health burden on communities worldwide, with early detection potentially reducing the incidence of developmental disorders and improving patients' communication skills.
Top 3 Risk Factors and Comorbidities for Autism
Risk Factors
1. Genetic Factors
Genetic components play crucial roles in Autism Spectrum Disorders (ASD), including gene mutations and copy-number variations. In 10% to 20% of cases, the cause of ASD is shown to be genetic. Parents of children with ASD often have mild forms of autistic-like characteristics. Research has found that the pairwise genetic distance (PGD) between spousal pairs with ASD-affected children was smaller than random pairs, and spousal relatedness correlated with severe forms of ASD. Specific genetic factors include haploinsufficiency of Shank3 (which encodes a scaffold protein at glutamatergic synapses) and MTHFR gene SNPs (677C>T rs1801133 and 1298A>C rs1801131). Genetic predisposition to ASD may involve as many as 10 genes.
2. Neuroinflammation and Biochemical Factors
Neuroinflammation plays a significant role in autism behaviors. ASD patients have remarkably higher levels of PGE2, COX-2, mPGES-1, and NF-κB compared to neurotypical controls. There is an imbalance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission, with a significant decrease in serum levels of GABA and GABA receptors and increase in serum glutamate levels in children with ASD. Other biochemical factors include oxidative stress occurring in early brain tissue development, mitochondrial dysfunction, and disorders of vital biochemical processes of methylation and transsulfuration.
3. Environmental and Prenatal Factors
Environmental factors are increasingly recognized as important in ASD development. The dramatic increase in ASD prevalence over recent decades has prompted searches for environmental triggers that would add to genetic predisposition. Many experts believe that abnormal brain development in autism occurs before 30 weeks' gestation in most instances. In utero rubella is a known cause of autism. Maternal personality disorders have been shown to be associated with increasing risk of autism.
Comorbidities
1. Intellectual and Neurological Comorbidities
Intellectual disability is the most prevalent comorbid condition at 70.3% of individuals with autism. Epilepsy affects 29.7% of people with autism. Changes in putamen volume show a strong and statistically significant association with ASD risk. Histone acetylation in the prefrontal cortex (PFC) is abnormally low in autism models.
2. Psychiatric and Behavioral Comorbidities
Attention deficit and hyperactivity disorder (ADHD) is present in 21.62% of individuals with autism. Children with ASD frequently experience anxiety. Parents of ASD children experience higher rates of psychiatric conditions including anxiety (60.8% vs 14.9% in controls) and depression (52% vs 25.7% in controls). Dysregulation (aggression, anxiety/depression, sleep problems) contributes to heterogeneity in children with ASD.
3. Gastrointestinal and Immunological Comorbidities
Up to 80% of children with ASD experience gastrointestinal (GI) symptoms such as constipation, diarrhea, and/or abdominal pain. Systemic immune activation and dysregulation, including increased pro-inflammatory cytokines, are frequently observed in ASD. The innate immune system may be impacted in ASD, as altered monocyte gene expression profiles and cytokine responses have been observed. Children with ASD and GI symptoms show different monocyte composition compared to ASD children without GI symptoms.
Aluminum-Containing Vaccines: Indications and Intervention Models Beyond Autism
Recent research has explored aluminum-containing vaccines for various indications beyond autism, with several notable intervention models being tested:
SARS-CoV-2 Vaccines
-
A 2023 study evaluated Alum-3M-052 as an adjuvant to improve antibody responses against SARS-CoV-2. The intervention model involved:
-
Female Balb/c mice immunized three times (days 0, 7, and 21)
-
Intramuscular administration of SARS-CoV-2 (B.1.617.2) spike protein with either Alum or Alum-3M-052
-
Results showed higher antibody titers and enhanced neutralization against SARS-CoV-2 variants
-
Another 2024 study developed an adjuvanted subunit vaccine using:
-
Recombinant receptor-binding domain (RBD) of SARS-CoV-2 spikes
-
Synthetic adjuvants targeting TLR7/8 (INI-4001) and TLR4 (INI-2002)
-
Co-delivery with aluminum hydroxide (AH) or aluminum phosphate (AP)
-
Testing in C57BL/6 mice showed that adding TLR ligands to alum promoted a Th1-mediated immunity shift and improved neutralizing antibody responses
-
A 2023 study evaluated heterologous three-dose vaccination schedules against Omicron BA.1 using:
-
Glycosylated and trimeric spike protein formulated with Alhydrogel
-
K18-hACE2 mice for intranasal challenge with Omicron BA.1
Clostridium perfringens Vaccine
-
A 2023 study evaluated nano selenium-enriched Levilactobacillus brevis (SeL) and its heat-inactivated form (HiSeL) as immune enhancers for:
-
Alum-adjuvanted, inactivated Clostridium perfringens type A vaccine
-
Testing in mouse and rabbit models
-
Results showed enhanced humoral immune response even at reduced vaccine doses (1/2 and 1/4 standard)
-
Confirmed in rabbits with improved IgG antibody production and α toxin-neutralizing antibodies
Allergen Immunotherapy
-
A 2019 study compared microcrystalline tyrosine (MCT) with conventional aluminum hydroxide (alum) in:
-
Wild-type, immune-signaling-deficient, and TCR-transgenic mice
-
Found that in sensitized mice, allergen immunotherapy with MCT-adjuvanted allergens caused fewer anaphylactic reactions compared to alum-adjuvanted allergens
Anthrax Vaccines
-
A 2020 study addressed PA instability issues in anthrax vaccines that are exacerbated when using aluminum adjuvants
-
Proposed new adjuvant compositions, dry formulations, and mutant PA forms resistant to proteolysis and deamidation
These studies demonstrate diverse applications of aluminum-containing vaccines beyond autism, with intervention models primarily utilizing mouse and rabbit models with various administration protocols and adjuvant combinations.
